胰高血糖素样肽-1 受体激动剂对脂联素浓度的影响：一项随机对照试验的荟萃分析。
Impact of glucagon-like peptide-1 receptor agonists on adiponectin concentrations: A meta-analysis of randomized controlled trials.
机构信息
Unidad de Investigación Biomédica, Delegación Durango, Instituto Mexicano del Seguro Social, Mexico.
Universidad Autonoma de Nuevo Leon, Endocrinology Division, University Hospital "Dr. José E. González", School of Medicine, Monterrey, NL, Mexico.
出版信息
Br J Clin Pharmacol. 2021 Nov;87(11):4140-4149. doi: 10.1111/bcp.14855. Epub 2021 Apr 29.
AIMS
Previous studies have reported an elevation in adiponectin concentrations using glucagon-like peptide-1 receptor agonists (GLP-1 RA) therapy; however, this possible pleiotropic effect is still uncertain. Thus, the objective of this meta-analysis of randomized controlled trials was to assess the impact of GLP-1 RA on adiponectin levels.
METHODS
This systematic review and meta-analysis included randomized controlled trials investigating the effect of GLP-1 RA on circulating adiponectin concentrations. Studies from PubMed, Web of Science, Scopus, and Google Scholar databases were included. A random-effects model and a sensitivity analysis using the leave 1-out method were conducted.
RESULTS
A meta-analysis of 20 randomized controlled trials involving 1497 individuals demonstrated a significant increase in adiponectin levels after GLP-1 RA administration (weighted mean difference [WMD]: 0.59 μg/mL, 95% confidence interval [CI]: 0.10, 1.08, P = .02). Particularly, liraglutide had a significant effect on adiponectin (WMD: 0.55 μg/mL, 95% CI: 0.04, 1.06, P = .04), while exenatide did not affect these concentrations (WMD: 0.60 μg/mL, 95% CI: -0.23, 1.42, P = .16).
CONCLUSION
GLP-1 RA treatment is associated with an increase in adiponectin levels.
目的
先前的研究报告称，胰高血糖素样肽-1 受体激动剂（GLP-1 RA）治疗可使脂联素浓度升高；然而，这种可能的多效性效应尚不确定。因此，本项随机对照试验的荟萃分析旨在评估 GLP-1 RA 对脂联素水平的影响。
方法
本系统评价和荟萃分析纳入了研究 GLP-1 RA 对循环脂联素浓度影响的随机对照试验。纳入了来自 PubMed、Web of Science、Scopus 和 Google Scholar 数据库的研究。采用随机效应模型和基于“留一法”的敏感性分析进行分析。
结果
对 20 项涉及 1497 人的随机对照试验进行荟萃分析表明，GLP-1 RA 给药后脂联素水平显著升高（加权均数差 [WMD]：0.59μg/mL，95%置信区间 [CI]：0.10，1.08，P=0.02）。特别是，利拉鲁肽对脂联素有显著影响（WMD：0.55μg/mL，95% CI：0.04，1.06，P=0.04），而艾塞那肽则不会影响这些浓度（WMD：0.60μg/mL，95% CI：-0.23，1.42，P=0.16）。
结论
GLP-1 RA 治疗与脂联素水平升高相关。
Zotero 插件